NASDAQ:ALRN Aileron Therapeutics (ALRN) Stock Price, News & Analysis → The ONE AI sSock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free ALRN Stock Alerts $5.41 -0.17 (-3.05%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$5.37▼$5.6750-Day Range$3.31▼$5.9452-Week Range$1.01▼$6.12Volume28,633 shsAverage Volume37,312 shsMarket Capitalization$26.45 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Aileron Therapeutics alerts: Email Address Aileron Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside66.4% Upside$9.00 Price TargetShort InterestHealthy1.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.01) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.54 out of 5 starsMedical Sector743rd out of 947 stocksPharmaceutical Preparations Industry347th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingAileron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Aileron Therapeutics has a forecasted upside of 66.4% from its current price of $5.41.Amount of Analyst CoverageAileron Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.20% of the float of Aileron Therapeutics has been sold short.Short Interest Ratio / Days to CoverAileron Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aileron Therapeutics has recently increased by 21.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAileron Therapeutics does not currently pay a dividend.Dividend GrowthAileron Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALRN. Previous Next 1.9 News and Social Media Coverage News SentimentAileron Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aileron Therapeutics this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 2 people have added Aileron Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aileron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.57% of the stock of Aileron Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.53% of the stock of Aileron Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aileron Therapeutics are expected to grow in the coming year, from ($2.01) to ($0.65) per share.Price to Book Value per Share RatioAileron Therapeutics has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About Aileron Therapeutics Stock (NASDAQ:ALRN)Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.Read More ALRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALRN Stock News HeadlinesMarch 16, 2024 | americanbankingnews.comShort Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Expands By 21.5%March 12, 2024 | markets.businessinsider.comAileron Therapeutics CEO Manuel Aivado Steps Down; Names Brian Windsor ReplacementMarch 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 12, 2024 | globenewswire.comAileron Therapeutics Announces CEO TransitionFebruary 15, 2024 | finance.yahoo.comAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventFebruary 15, 2024 | globenewswire.comAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventFebruary 1, 2024 | finance.yahoo.comAileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024January 30, 2024 | msn.comAileron Therapeutics Announces Director Nomination DetailsMarch 18, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.January 30, 2024 | msn.comAileron Therapeutics Announces 2024 Annual Meeting PlansDecember 27, 2023 | benzinga.comAileron Therapeutics Stock (NASDAQ:ALRN) Dividends: History, Yield and DatesDecember 15, 2023 | msn.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 0.43%December 1, 2023 | realmoney.thestreet.comAileron Therapeutics upgraded to Buy at Ladenburg after Lung Therapeutics dealDecember 1, 2023 | realmoney.thestreet.comAileron Therapeutics upgraded to Buy from Neutral at LadenburgNovember 5, 2023 | benzinga.comAileron Therapeutics Director Awarded $6K Worth of Stock OptionsNovember 1, 2023 | msn.comAileron gains after all-stock deal to acquire Lung TherapeuticsOctober 31, 2023 | finance.yahoo.comAileron Therapeutics Announces Acquisition of Lung TherapeuticsApril 4, 2023 | finance.yahoo.comBears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' NowMarch 22, 2023 | finance.yahoo.comAileron Therapeutics, Inc. (ALRN)March 14, 2023 | finance.yahoo.comAileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowMarch 3, 2023 | msn.comLooking Into Aileron Therapeutics's Recent Short InterestFebruary 23, 2023 | markets.businessinsider.comJonesTrading Keeps Their Hold Rating on Aileron Therapeutics (ALRN)February 22, 2023 | finance.yahoo.comCancer drugmaker down to 3 employees after trial failureFebruary 21, 2023 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.06%February 21, 2023 | seekingalpha.comAileron off 38% on plans to explore sale after setback for cancer candidateFebruary 21, 2023 | finance.yahoo.comAileron Therapeutics Shelves Development On Chemoprotection Agent, Shares FallFebruary 21, 2023 | markets.businessinsider.comAileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924See More Headlines Receive ALRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today3/18/2024Next Earnings (Estimated)3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALRN CUSIPN/A CIK1420565 Webwww.aileronrx.com Phone(617) 995-0900FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$9.00 Low Stock Price Target$9.00 Potential Upside/Downside+65.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-83.80% Return on Assets-72.25% Debt Debt-to-Equity RatioN/A Current Ratio7.88 Quick Ratio7.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book1.33Miscellaneous Outstanding Shares4,890,000Free Float4,613,000Market Cap$26.65 million OptionableNot Optionable Beta2.19 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Manuel C. Aivado M.D. (Age 54)Ph.D., CEO & Director Comp: $630.74kDr. Brian Windsor Ph.D. (Age 57)COO & President Comp: $511.55kMs. Susan L. Drexler CPA (Age 54)M.B.A., Interim CFO, Principal Financial Officer & Principal Accounting Officer Key CompetitorsLisata TherapeuticsNASDAQ:LSTACalciMedicaNASDAQ:CALCUnity BiotechnologyNASDAQ:UBXTherapeuticsMDNASDAQ:TXMDBioVieNASDAQ:BIVIView All CompetitorsInsiders & InstitutionsTexas Capital Bank Wealth Management Services IncBought 15,773 shares on 2/8/2024Ownership: 0.323%Sigma Planning CorpBought 16,580 shares on 2/1/2024Ownership: 0.339%James Brian WindsorBought 225 shares on 12/15/2023Total: $758.25 ($3.37/share)James Brian WindsorBought 5,076 shares on 11/20/2023Total: $9,999.72 ($1.97/share)View All Insider TransactionsView All Institutional Transactions ALRN Stock Analysis - Frequently Asked Questions Should I buy or sell Aileron Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ALRN shares. View ALRN analyst ratings or view top-rated stocks. What is Aileron Therapeutics' stock price target for 2024? 1 brokers have issued 1-year price targets for Aileron Therapeutics' shares. Their ALRN share price targets range from $9.00 to $9.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 66.4% from the stock's current price. View analysts price targets for ALRN or view top-rated stocks among Wall Street analysts. How have ALRN shares performed in 2024? Aileron Therapeutics' stock was trading at $3.05 at the beginning of the year. Since then, ALRN shares have increased by 77.4% and is now trading at $5.41. View the best growth stocks for 2024 here. Are investors shorting Aileron Therapeutics? Aileron Therapeutics saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 37,900 shares, an increase of 21.5% from the February 14th total of 31,200 shares. Based on an average trading volume of 99,600 shares, the days-to-cover ratio is presently 0.4 days. Approximately 1.2% of the shares of the stock are sold short. View Aileron Therapeutics' Short Interest. When is Aileron Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024. View our ALRN earnings forecast. How were Aileron Therapeutics' earnings last quarter? Aileron Therapeutics, Inc. (NASDAQ:ALRN) issued its quarterly earnings data on Friday, November, 12th. The company reported ($1.40) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.40). When did Aileron Therapeutics' stock split? Shares of Aileron Therapeutics reverse split on Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Aileron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV). When did Aileron Therapeutics IPO? (ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. Who are Aileron Therapeutics' major shareholders? Aileron Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sigma Planning Corp (0.34%) and Texas Capital Bank Wealth Management Services Inc (0.32%). View institutional ownership trends. How do I buy shares of Aileron Therapeutics? Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALRN) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceDid you make $29,000 two days with AI options trades?Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.